<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-42 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-42</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-42</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-2.html">extraction-schema-2</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered molecular drivers, mechanisms, or pathways in lung adenocarcinomas lacking known RTK/RAS/RAF pathway alterations, including genetic, epigenetic, metabolic, or microenvironmental factors, as well as any supporting or refuting evidence.</div>
                <p><strong>Paper ID:</strong> paper-fd8c293ec07c9a03f0de0c9eb752266f199977b1</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/fd8c293ec07c9a03f0de0c9eb752266f199977b1" target="_blank">A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing.</a></p>
                <p><strong>Paper Venue:</strong> Genome Research</p>
                <p><strong>Paper TL;DR:</strong> It is demonstrated that a subset of NSCLCs could be caused by a fusion of KIF5B and RET, and suggested the chimeric oncogene as a promising molecular target for the personalized diagnosis and treatment of lung cancer.</p>
                <p><strong>Cost:</strong> 0.018</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e42.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e42.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered molecular drivers, mechanisms, or pathways in lung adenocarcinomas lacking known RTK/RAS/RAF pathway alterations, including genetic, epigenetic, metabolic, or microenvironmental factors, as well as any supporting or refuting evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>KIF5B-RET</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Kinesin family member 5B — RET proto-oncogene fusion</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>An intrachromosomal 10.6 Mb inversion on chr10 producing a chimeric oncoprotein that fuses the N-terminal coiled-coil/dimerization domain of KIF5B to the C-terminal tyrosine kinase domain of RET, resulting in high-level RET kinase expression in lung adenocarcinoma samples lacking EGFR/KRAS/ALK alterations.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Whole-genome sequencing (WGS) + transcriptome (RNA-seq); PCR and Sanger validation</td>
                        </tr>
                        <tr>
                            <td><strong>cohort_description</strong></td>
                            <td>Index case AK55 (33-yr-old never-smoker with metastatic lung adenocarcinoma) profiled by WGS (liver metastasis and blood) and RNA-seq (liver metastasis); replication cohort of 20 primary lung adenocarcinomas (5 triple-negative [EGFR/KRAS/EML4-ALK negative], 15 double-negative [EGFR and EML4-ALK negative, KRAS unknown]). KIF5B-RET was detected in AK55 and in 2 additional primary tumors (LC_S2, LC_S6) — 3 cases out of 21 total samples analyzed.</td>
                        </tr>
                        <tr>
                            <td><strong>driver_negative_definition</strong></td>
                            <td>Tumors were considered driver-negative when they tested negative for the canonical RTK/RAS/RAF pathway alterations assessed clinically: EGFR (exons 18-21), KRAS (exon 2), and EML4-ALK fusion (by FISH); AK55 was negative for EGFR, KRAS, and EML4-ALK.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_driver</strong></td>
                            <td>KIF5B-RET gene fusion (chimeric RET tyrosine kinase)</td>
                        </tr>
                        <tr>
                            <td><strong>driver_type</strong></td>
                            <td>Genetic — gene fusion (structural rearrangement/inversion) producing a chimeric oncoprotein and overexpression</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_summary</strong></td>
                            <td>Multiple orthogonal lines of evidence from this paper: (1) RNA-seq: 34 discordant paired-end reads and 60 spanning reads across the KIF5B exon16–RET exon12 junction in AK55; (2) WGS: reads supporting a 10.6 Mb inversion on chr10 linking KIF5B and RET with breakpoint validation by inversion-specific PCR and Sanger sequencing in primary tumor and metastases; (3) exon-level expression: RET exons 12-20 are highly expressed (~10x) in fusion-positive samples compared with RET-wild-type lung cancers; (4) recurrence: fusion identified in 2 additional primary lung adenocarcinomas in replication cohort (total 3/21); (5) predicted protein retains KIF5B coiled-coil dimerization domain and full RET kinase domain, a mechanism known to activate RET in other cancers; (6) prior biological plausibility because RET is a known oncogene in papillary thyroid carcinoma and other tumors, and RET activation can transform cells (supported by cited transgenic mouse data).</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence</strong></td>
                            <td>Limited sample size and epidemiologic uncertainty (3/21 cases); the study did not present direct biochemical demonstration of RET autophosphorylation or in vitro/in vivo transformation assays within this paper (the abstract states the chimera 'could spontaneously induce cellular transformation' but the main evidence provided is genomic/transcriptomic and recurrence/structural validation rather than functional cell-based assays); frequency estimate is preliminary and requires larger studies; alternative mechanisms of RET activation (amplification, other fusion partners, regulatory mutations) were not exhaustively excluded across broader cohorts.</td>
                        </tr>
                        <tr>
                            <td><strong>model_or_hypothesis</strong></td>
                            <td>A chromosomal inversion brings the KIF5B promoter and N-terminal coiled-coil dimerization domain into fusion with the RET kinase domain, driving aberrant, ligand-independent RET dimerization and autophosphorylation and producing oncogenic RTK signaling in tumors that lack canonical EGFR/KRAS/ALK alterations.</td>
                        </tr>
                        <tr>
                            <td><strong>reference</strong></td>
                            <td>Ju YS et al., A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res. 2012;22:436-445.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing.', 'publication_date_yy_mm': '2012-03'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e42.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e42.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered molecular drivers, mechanisms, or pathways in lung adenocarcinomas lacking known RTK/RAS/RAF pathway alterations, including genetic, epigenetic, metabolic, or microenvironmental factors, as well as any supporting or refuting evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>RET overexpression</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Overexpression of RET proto-oncogene (exons 12-20)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>High-level expression of RET kinase-domain exons observed in fusion-positive lung tumors and noted also in a small subset of TCGA lung adenocarcinomas; proposed as an oncogenic mechanism either via fusion, amplification, or regulatory mutation.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Transcriptome sequencing (RNA-seq) with exon-level expression analysis; cross-reference to TCGA expression data</td>
                        </tr>
                        <tr>
                            <td><strong>cohort_description</strong></td>
                            <td>AK55 index tumor (liver metastasis) with exon-level RNA-seq; replication cohort of primary tumors; comparison to public TCGA expression profiles (32 samples referenced for RET overexpression assessment).</td>
                        </tr>
                        <tr>
                            <td><strong>driver_negative_definition</strong></td>
                            <td>Defined as tumors lacking EGFR/KRAS/EML4-ALK alterations; RET overexpression was evaluated as an alternative activation mechanism in these driver-negative contexts.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_driver</strong></td>
                            <td>RET overexpression (driven by KIF5B promoter activity in fusion-positive cases or potentially by amplification/regulatory mutation or other fusions)</td>
                        </tr>
                        <tr>
                            <td><strong>driver_type</strong></td>
                            <td>Genetic/expressional — gene overexpression (resulting from fusion-driven promoter activity or other genomic events)</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_summary</strong></td>
                            <td>In fusion-positive samples, RET exons downstream of the fusion breakpoint (exons 12–20) are expressed ~10-fold higher than in lung cancers without RET rearrangement; in TCGA data, 3/32 lung adenocarcinomas showed RET overexpression, suggesting RET activation may occur by multiple mechanisms.</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence</strong></td>
                            <td>Small numbers in both the study cohort and TCGA comparison limit inference; overexpression alone was not functionally validated as oncogenic in these specific lung tumors in this paper; some RET-overexpressing cases in broader datasets may not harbor RET fusions, and the mechanism of overexpression (fusion vs amplification vs regulatory mutation) was not resolved for all cases.</td>
                        </tr>
                        <tr>
                            <td><strong>model_or_hypothesis</strong></td>
                            <td>RET activation in driver-negative lung adenocarcinomas may occur via chimeric fusions that place RET under active promoters (e.g., KIF5B), or via other genomic events that increase RET expression, leading to oncogenic RTK signaling independent of canonical EGFR/KRAS/RAF pathway mutations.</td>
                        </tr>
                        <tr>
                            <td><strong>reference</strong></td>
                            <td>Ju YS et al., A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res. 2012;22:436-445.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing.', 'publication_date_yy_mm': '2012-03'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e42.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e42.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered molecular drivers, mechanisms, or pathways in lung adenocarcinomas lacking known RTK/RAS/RAF pathway alterations, including genetic, epigenetic, metabolic, or microenvironmental factors, as well as any supporting or refuting evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>KIF5B promoter / coiled-coil dimerization</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>KIF5B promoter-driven expression and coiled-coil-mediated dimerization mechanism</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Mechanistic model where the ubiquitously active KIF5B promoter drives expression of the fusion transcript and the KIF5B coiled-coil domain mediates constitutive dimerization of the chimeric RET kinase, enabling ligand-independent activation.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Inferred mechanistic model based on domain annotation, exon structure, and expression data from RNA-seq; protein-structure prediction (PHYRE2) was used to visualize the chimeric protein.</td>
                        </tr>
                        <tr>
                            <td><strong>cohort_description</strong></td>
                            <td>AK55 and replication fusion-positive primary tumors (LC_S2, LC_S6); exon mapping showed retention of KIF5B N-terminal coiled-coil and RET kinase domain.</td>
                        </tr>
                        <tr>
                            <td><strong>driver_negative_definition</strong></td>
                            <td>Tumors negative for EGFR/KRAS/EML4-ALK where fusion-mediated promoter swapping may be an alternative activation mechanism.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_driver</strong></td>
                            <td>Promoter swapping and coiled-coil-mediated dimerization leading to RET kinase activation</td>
                        </tr>
                        <tr>
                            <td><strong>driver_type</strong></td>
                            <td>Genetic/structural — promoter hijacking and protein domain-mediated activation</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_summary</strong></td>
                            <td>Fusion transcripts place RET kinase exons under KIF5B sequence; predicted fusion proteins retain KIF5B coiled-coil domains (lengths preserved across samples) and RET kinase domain; expression data show high RET exon expression downstream of fusion breakpoints; precedent from RET fusions in papillary thyroid carcinoma shows dimerization-activated RET kinases.</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence</strong></td>
                            <td>No direct biochemical assays in this paper (e.g., co-immunoprecipitation, autophosphorylation, or downstream signaling activation) are shown to demonstrate constitutive dimerization/activation specifically for these KIF5B-RET isoforms; functional consequences are inferred by analogy to known RET fusion mechanisms.</td>
                        </tr>
                        <tr>
                            <td><strong>model_or_hypothesis</strong></td>
                            <td>KIF5B provides both an active promoter in lung tissue and a multimerization domain that enforces constitutive dimerization of the RET kinase, leading to autonomous RET signaling and tumorigenesis in the absence of upstream RTK/RAS/RAF mutations.</td>
                        </tr>
                        <tr>
                            <td><strong>reference</strong></td>
                            <td>Ju YS et al., A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res. 2012;22:436-445.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing.', 'publication_date_yy_mm': '2012-03'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e42.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e42.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered molecular drivers, mechanisms, or pathways in lung adenocarcinomas lacking known RTK/RAS/RAF pathway alterations, including genetic, epigenetic, metabolic, or microenvironmental factors, as well as any supporting or refuting evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Genomic rearrangement mechanisms</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Error-prone double-strand break repair mechanisms (NHEJ, FoSTeS, MMBIR) and DNA secondary-structure fragility (G-quadruplex)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Proposed mechanistic contributors to the 10.6 Mb inversion producing KIF5B-RET: a 1-bp deletion near the breakpoint suggests error-prone repair pathways (nonhomologous end joining, fork stalling/template switching, microhomology-mediated break-induced replication), and predicted G-quadruplex structures near the RET breakpoint indicate local fragility that may predispose to rearrangement.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Whole-genome sequencing breakpoint analysis with local sequence motif prediction (G-quadruplex prediction); inference of DNA repair mechanisms from sequence features (1-bp deletion adjacent to breakpoint).</td>
                        </tr>
                        <tr>
                            <td><strong>cohort_description</strong></td>
                            <td>Breakpoints characterized in AK55 primary and metastatic tumor DNA (inversion breakpoint chr10:32,351,306-42,931,601; 1-bp deletion at chr10:42,931,604).</td>
                        </tr>
                        <tr>
                            <td><strong>driver_negative_definition</strong></td>
                            <td>Context: tumors lacking canonical RTK/RAS/RAF drivers where structural variants may be the oncogenic event; mechanisms of rearrangement are proposed to explain generation of such fusions.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_driver</strong></td>
                            <td>Mechanistic drivers of fusion formation: error-prone DSB repair (NHEJ/FoSTeS/MMBIR) and local DNA fragility from G-quadruplex formation</td>
                        </tr>
                        <tr>
                            <td><strong>driver_type</strong></td>
                            <td>Mechanistic/genomic instability — mechanisms producing structural variants (not a tumor-driving gene per se but a process generating oncogenic fusions)</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_summary</strong></td>
                            <td>Observed 1-bp deletion adjacent to the inversion breakpoint (consistent with error-prone repair); computational prediction of a G-quadruplex structure ~100 bp upstream of RET rearrangement hotspot, which is known from literature to be associated with fragility and rearrangement-prone regions.</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence</strong></td>
                            <td>These are inferential and correlative observations; no experimental demonstration (e.g., assays of break formation or repair pathway usage) is provided in this paper to prove causality for this specific inversion.</td>
                        </tr>
                        <tr>
                            <td><strong>model_or_hypothesis</strong></td>
                            <td>Local sequence fragility (e.g., G-quadruplexes) predisposes RET locus to breakage; subsequent error-prone DSB repair mechanisms generate the inversion that creates KIF5B-RET fusions.</td>
                        </tr>
                        <tr>
                            <td><strong>reference</strong></td>
                            <td>Ju YS et al., A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res. 2012;22:436-445.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing.', 'publication_date_yy_mm': '2012-03'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e42.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e42.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered molecular drivers, mechanisms, or pathways in lung adenocarcinomas lacking known RTK/RAS/RAF pathway alterations, including genetic, epigenetic, metabolic, or microenvironmental factors, as well as any supporting or refuting evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>RNA A-to-I editing candidates</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Adenosine-to-inosine (A-to-I) RNA editing events detected in tumor transcriptome</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Transcriptome analysis identified 10 candidate A-to-I RNA editing sites in the liver metastatic tumor of AK55, but their predicted functional impacts were judged insufficient to be driving events for transformation in this case.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Transcriptome sequencing (RNA-seq) with paired DNA comparison to call RNA editing events (conservative criteria applied).</td>
                        </tr>
                        <tr>
                            <td><strong>cohort_description</strong></td>
                            <td>Single index tumor (AK55) liver metastasis compared to germline (blood) WGS.</td>
                        </tr>
                        <tr>
                            <td><strong>driver_negative_definition</strong></td>
                            <td>Tumor lacked EGFR/KRAS/ALK drivers; RNA editing was evaluated as an alternative source of oncogenic variation.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_driver</strong></td>
                            <td>A-to-I RNA editing (candidate sites) — proposed/tested but not supported as drivers here</td>
                        </tr>
                        <tr>
                            <td><strong>driver_type</strong></td>
                            <td>Post-transcriptional/epigenetic-like RNA modification</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_summary</strong></td>
                            <td>10 candidate A-to-I editing sites passed conservative calling criteria (≥10 high-quality mismatches, ≥20% read-allele frequency, absent in genomic DNA), but their predicted functional impacts were not sufficient to support a driver role.</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence</strong></td>
                            <td>Authors conclude the editing candidates' functional impacts were not sufficient to be fundamental driver mutations; no functional follow-up was provided to test oncogenicity of any specific edited transcripts.</td>
                        </tr>
                        <tr>
                            <td><strong>model_or_hypothesis</strong></td>
                            <td>While RNA editing can alter protein sequences or regulation, in this tumor the detected A-to-I events are unlikely to explain oncogenesis compared with the structural KIF5B-RET fusion.</td>
                        </tr>
                        <tr>
                            <td><strong>reference</strong></td>
                            <td>Ju YS et al., A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res. 2012;22:436-445.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing.', 'publication_date_yy_mm': '2012-03'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e42.5">
                <h3 class="extraction-instance">Extracted Data Instance 5 (e42.5)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered molecular drivers, mechanisms, or pathways in lung adenocarcinomas lacking known RTK/RAS/RAF pathway alterations, including genetic, epigenetic, metabolic, or microenvironmental factors, as well as any supporting or refuting evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Non-driver somatic SNVs/indels</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Somatic nonsynonymous single-nucleotide variants and coding indels (noncanonical drivers)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Whole-genome sequencing identified 10 somatic coding mutations (8 SNVs, 2 indels) in the metastatic tumor that were not in canonical oncogenes (EGFR, KRAS, BRAF, PIK3CA, AKT1, MAP2K1, MET) and were predicted unlikely to be driver events.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Whole-genome sequencing with variant calling and annotation (including SIFT in silico prediction).</td>
                        </tr>
                        <tr>
                            <td><strong>cohort_description</strong></td>
                            <td>AK55 liver metastasis compared to matched blood WGS; 10 nonsynonymous somatic mutations reported.</td>
                        </tr>
                        <tr>
                            <td><strong>driver_negative_definition</strong></td>
                            <td>Driver-negative with respect to canonical RTK/RAS/RAF alterations; somatic SNVs were assessed as alternative potential drivers.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_driver</strong></td>
                            <td>Individual somatic SNVs/indels (none proposed as drivers in this paper)</td>
                        </tr>
                        <tr>
                            <td><strong>driver_type</strong></td>
                            <td>Genetic — somatic point mutations/indels</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_summary</strong></td>
                            <td>10 coding somatic mutations were identified but none occurred in known lung cancer driver genes; functional annotation and SIFT predictions suggested these were unlikely to have major impact on transformation; authors therefore considered them unlikely drivers.</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence</strong></td>
                            <td>It is possible some of these mutations have context-dependent effects or contribute as cooperating events; authors note some may arise during metastasis rather than initial transformation.</td>
                        </tr>
                        <tr>
                            <td><strong>model_or_hypothesis</strong></td>
                            <td>The tumor's primary driver is structural (KIF5B-RET fusion) rather than somatic point mutations; the identified coding SNVs are likely passengers or later events.</td>
                        </tr>
                        <tr>
                            <td><strong>reference</strong></td>
                            <td>Ju YS et al., A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res. 2012;22:436-445.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing.', 'publication_date_yy_mm': '2012-03'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e42.6">
                <h3 class="extraction-instance">Extracted Data Instance 6 (e42.6)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered molecular drivers, mechanisms, or pathways in lung adenocarcinomas lacking known RTK/RAS/RAF pathway alterations, including genetic, epigenetic, metabolic, or microenvironmental factors, as well as any supporting or refuting evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Adjacent intrachromosomal fusions (likely passengers)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Multiple short-range intrachromosomal fusion transcripts between adjacent genes (<135 kb)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Transcriptome analysis detected 52 candidate fusion transcripts, 49 (94.2%) of which were intrachromosomal fusions between adjacent genes (<135 kb), which the authors consider unlikely to have oncogenic roles and possibly represent readthroughs or artifacts.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Transcriptome sequencing (RNA-seq) fusion detection pipeline with filtering and manual curation</td>
                        </tr>
                        <tr>
                            <td><strong>cohort_description</strong></td>
                            <td>AK55 liver metastasis RNA-seq revealed 52 fusion candidates; most were short-range intrachromosomal events.</td>
                        </tr>
                        <tr>
                            <td><strong>driver_negative_definition</strong></td>
                            <td>Genome lacked canonical RTK/RAS/RAF mutations, prompting a search for alternative fusion drivers; majority of detected fusions were judged unlikely drivers.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_driver</strong></td>
                            <td>No specific adjacent short-range fusions were proposed as drivers in this study; they are listed as abundant but likely nonfunctional.</td>
                        </tr>
                        <tr>
                            <td><strong>driver_type</strong></td>
                            <td>Genetic — transcript-level fusions/readthroughs (likely passenger events)</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_summary</strong></td>
                            <td>49/52 fusion candidates were intrachromosomal between adjacent genes (<135 kb); only KIF5B-RET had supporting genomic rearrangement evidence in WGS; other short-range fusions lacked corresponding genomic rearrangement evidence and are consistent with readthrough or transcriptional noise.</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence</strong></td>
                            <td>Authors note one interchromosomal fusion (RSPO1-HP) likely reflects liver-specific expression (HP highly expressed) rather than oncogenic rearrangement; absence of genomic rearrangement evidence argues against functional significance for most short-range fusions.</td>
                        </tr>
                        <tr>
                            <td><strong>model_or_hypothesis</strong></td>
                            <td>Short-range fused transcripts are common in RNA-seq data and often represent readthrough transcription or artifacts rather than drivers; emphasis placed on fusions with genomic rearrangement support for driver candidacy.</td>
                        </tr>
                        <tr>
                            <td><strong>reference</strong></td>
                            <td>Ju YS et al., A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res. 2012;22:436-445.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing.', 'publication_date_yy_mm': '2012-03'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>RET and NTRK1 proto-oncogenes in human diseases <em>(Rating: 2)</em></li>
                <li>KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer <em>(Rating: 2)</em></li>
                <li>Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer <em>(Rating: 1)</em></li>
                <li>A microhomology-mediated break-induced replication model for the origin of human copy number variation <em>(Rating: 1)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>